Logo image of BLFS

BIOLIFE SOLUTIONS INC (BLFS) Stock Fundamental Analysis

NASDAQ:BLFS - Nasdaq - US09062W2044 - Common Stock - Currency: USD

22.32  -0.03 (-0.13%)

After market: 22.32 0 (0%)

Fundamental Rating

4

Overall BLFS gets a fundamental rating of 4 out of 10. We evaluated BLFS against 55 industry peers in the Life Sciences Tools & Services industry. BLFS has a great financial health rating, but its profitability evaluates not so good. While showing a medium growth rate, BLFS is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

BLFS had negative earnings in the past year.
BLFS had a positive operating cash flow in the past year.
BLFS had negative earnings in 4 of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: BLFS reported negative operating cash flow in multiple years.
BLFS Yearly Net Income VS EBIT VS OCF VS FCFBLFS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M

1.2 Ratios

With a decent Return On Assets value of -5.05%, BLFS is doing good in the industry, outperforming 61.82% of the companies in the same industry.
With a decent Return On Equity value of -5.78%, BLFS is doing good in the industry, outperforming 63.64% of the companies in the same industry.
Industry RankSector Rank
ROA -5.05%
ROE -5.78%
ROIC N/A
ROA(3y)-17.53%
ROA(5y)-10.68%
ROE(3y)-21.44%
ROE(5y)-13.06%
ROIC(3y)N/A
ROIC(5y)N/A
BLFS Yearly ROA, ROE, ROICBLFS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150 -200

1.3 Margins

Looking at the Gross Margin, with a value of 59.19%, BLFS is in the better half of the industry, outperforming 74.55% of the companies in the same industry.
BLFS's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for BLFS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 59.19%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y28.1%
GM growth 5Y-0.79%
BLFS Yearly Profit, Operating, Gross MarginsBLFS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100

More info and screens

7

2. Health

2.1 Basic Checks

BLFS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, BLFS has more shares outstanding
The number of shares outstanding for BLFS has been increased compared to 5 years ago.
Compared to 1 year ago, BLFS has an improved debt to assets ratio.
BLFS Yearly Shares OutstandingBLFS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
BLFS Yearly Total Debt VS Total AssetsBLFS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

An Altman-Z score of 11.97 indicates that BLFS is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 11.97, BLFS belongs to the best of the industry, outperforming 96.36% of the companies in the same industry.
BLFS has a debt to FCF ratio of 5.62. This is a neutral value as BLFS would need 5.62 years to pay back of all of its debts.
BLFS has a better Debt to FCF ratio (5.62) than 65.45% of its industry peers.
BLFS has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
BLFS's Debt to Equity ratio of 0.01 is fine compared to the rest of the industry. BLFS outperforms 69.09% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF 5.62
Altman-Z 11.97
ROIC/WACCN/A
WACC10.62%
BLFS Yearly LT Debt VS Equity VS FCFBLFS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M 400M

2.3 Liquidity

A Current Ratio of 4.54 indicates that BLFS has no problem at all paying its short term obligations.
BLFS's Current ratio of 4.54 is fine compared to the rest of the industry. BLFS outperforms 70.91% of its industry peers.
A Quick Ratio of 3.66 indicates that BLFS has no problem at all paying its short term obligations.
With a decent Quick ratio value of 3.66, BLFS is doing good in the industry, outperforming 67.27% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.54
Quick Ratio 3.66
BLFS Yearly Current Assets VS Current LiabilitesBLFS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M

More info and screens

6

3. Growth

3.1 Past

BLFS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 72.64%, which is quite impressive.
The Revenue has grown by 8.44% in the past year. This is quite good.
Measured over the past years, BLFS shows a very strong growth in Revenue. The Revenue has been growing by 24.59% on average per year.
EPS 1Y (TTM)72.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%95.65%
Revenue 1Y (TTM)8.44%
Revenue growth 3Y-11.63%
Revenue growth 5Y24.59%
Sales Q2Q%-24.54%

3.2 Future

Based on estimates for the next years, BLFS will show a very strong growth in Earnings Per Share. The EPS will grow by 44.23% on average per year.
BLFS is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 17.05% yearly.
EPS Next Y81.67%
EPS Next 2Y46.42%
EPS Next 3Y44.23%
EPS Next 5YN/A
Revenue Next Year-8.73%
Revenue Next 2Y3.6%
Revenue Next 3Y10.13%
Revenue Next 5Y17.05%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
BLFS Yearly Revenue VS EstimatesBLFS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M 400M 500M
BLFS Yearly EPS VS EstimatesBLFS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 0.5 -0.5 -1 -1.5 -2

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

BLFS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
BLFS is valuated quite expensively with a Price/Forward Earnings ratio of 303.92.
BLFS's Price/Forward Earnings is on the same level as the industry average.
BLFS's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 22.13.
Industry RankSector Rank
PE N/A
Fwd PE 303.92
BLFS Price Earnings VS Forward Price EarningsBLFS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 100 200 300

4.2 Price Multiples

BLFS's Enterprise Value to EBITDA is on the same level as the industry average.
The rest of the industry has a similar Price/Free Cash Flow ratio as BLFS.
Industry RankSector Rank
P/FCF 374.31
EV/EBITDA 629.98
BLFS Per share dataBLFS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
BLFS's earnings are expected to grow with 44.23% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y46.42%
EPS Next 3Y44.23%

More info and screens

0

5. Dividend

5.1 Amount

BLFS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOLIFE SOLUTIONS INC

NASDAQ:BLFS (5/29/2025, 8:00:01 PM)

After market: 22.32 0 (0%)

22.32

-0.03 (-0.13%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)08-06 2025-08-06/amc
Inst Owners102.53%
Inst Owner Change2.96%
Ins Owners1.69%
Ins Owner Change2.23%
Market Cap1.06B
Analysts82.67
Price Target31.96 (43.19%)
Short Float %8.54%
Short Ratio7.1
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)275.74%
Min EPS beat(2)55%
Max EPS beat(2)496.49%
EPS beat(4)3
Avg EPS beat(4)81.09%
Min EPS beat(4)-246.6%
Max EPS beat(4)496.49%
EPS beat(8)5
Avg EPS beat(8)37.34%
EPS beat(12)7
Avg EPS beat(12)-17.12%
EPS beat(16)9
Avg EPS beat(16)-17.11%
Revenue beat(2)2
Avg Revenue beat(2)10.35%
Min Revenue beat(2)3.34%
Max Revenue beat(2)17.36%
Revenue beat(4)4
Avg Revenue beat(4)14.07%
Min Revenue beat(4)3.34%
Max Revenue beat(4)19.6%
Revenue beat(8)4
Avg Revenue beat(8)3.22%
Revenue beat(12)6
Avg Revenue beat(12)1.28%
Revenue beat(16)10
Avg Revenue beat(16)2.27%
PT rev (1m)0%
PT rev (3m)1.4%
EPS NQ rev (1m)0%
EPS NQ rev (3m)11.9%
EPS NY rev (1m)32.1%
EPS NY rev (3m)55.28%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.8%
Revenue NY rev (1m)0.74%
Revenue NY rev (3m)1.72%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 303.92
P/S 10.93
P/FCF 374.31
P/OCF 125.91
P/B 3.04
P/tB 8.36
EV/EBITDA 629.98
EPS(TTM)-0.29
EYN/A
EPS(NY)0.07
Fwd EY0.33%
FCF(TTM)0.06
FCFY0.27%
OCF(TTM)0.18
OCFY0.79%
SpS2.04
BVpS7.34
TBVpS2.67
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -5.05%
ROE -5.78%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 59.19%
FCFM 2.92%
ROA(3y)-17.53%
ROA(5y)-10.68%
ROE(3y)-21.44%
ROE(5y)-13.06%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y28.1%
GM growth 5Y-0.79%
F-Score6
Asset Turnover0.24
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF 5.62
Debt/EBITDA 3.26
Cap/Depr 64.6%
Cap/Sales 5.76%
Interest Coverage N/A
Cash Conversion 550.33%
Profit Quality N/A
Current Ratio 4.54
Quick Ratio 3.66
Altman-Z 11.97
F-Score6
WACC10.62%
ROIC/WACCN/A
Cap/Depr(3y)80.15%
Cap/Depr(5y)101.86%
Cap/Sales(3y)10.07%
Cap/Sales(5y)11.77%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)72.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%95.65%
EPS Next Y81.67%
EPS Next 2Y46.42%
EPS Next 3Y44.23%
EPS Next 5YN/A
Revenue 1Y (TTM)8.44%
Revenue growth 3Y-11.63%
Revenue growth 5Y24.59%
Sales Q2Q%-24.54%
Revenue Next Year-8.73%
Revenue Next 2Y3.6%
Revenue Next 3Y10.13%
Revenue Next 5Y17.05%
EBIT growth 1Y87.12%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year295.82%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y111.95%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y167.46%
OCF growth 3YN/A
OCF growth 5Y47.44%